DOCSLIB.ORG

Glial Changes in Atypical Parkinsonian Syndromes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Glial changes in atypical parkinsonian syndromes Yun Ju Christine Song A thesis submitted in fulfilment of the requirements for the degree of Doctor of Philosophy August 2008 University of New South Wales Department of Anatomy Supervisors: Professor Glenda M Halliday Dr Yue Huang 1 Acknowledgements It feels surreal realising that I have come to the end of this unbelievably challenging but rewarding journey. I could not have come this far without the amazing help and guidance from so many important people and I am deeply grateful to everybody who has contributed to the steps I have taken in completing this journey. To my supervisor Glenda Halliday, thank you so much for all your encouragement and guidance. I have continuously learnt so much from you and there have been countless times where I have been in constant awe of your drive, passion and knowledge about these movement disorders. Thank you for all your teachings and enthusiasm for my work, and believing that I could achieve this. I could not have come this far without such a first-class supervisor. To my co-supervisor Yue Huang, your passion for MSA pushed me to search for more and you always helped me to think from a different perspective. I have learnt many things from you and I thank you for your support. My dearest friend and lab manager Heather, your meticulous training and perfectionism in the lab and has helped me to achieve this much. Thank you for your technical guidance, I have the deepest regard for you, both as a teacher and friend. Karen, my second lab manager, thanks for being so helpful and supportive right to the very end. You have become such a dear friend and I appreciate all that you have done for me. Heidi, I owe so much to you, thank you for your patience and turning my images into artwork. I thank you Farid, Claire and Emma for all your words of wisdom and Fabs for all your technical support. To my collaborators Professor Poul Henning Jensen and Dr Paul Lockhart, your enthusiasm and interest in these glial proteins is what started this project and I thank you for your guidance and encouragement. I was so fortunate to do part of my PhD at the Queen Square Brain Bank. I owe so much to Professor Tamas 2 Revesz who taught me the beauty of neuropathology. Spending endless hours on the microscope with you and your encouragement and teachings has contributed so much to this journey, thank you. Dr Janice Holton, thank you for your ongoing support and faith in me as a researcher. Thank you to my friend and supervisor Dr Tammaryn Lashley, you are an amazing super-woman that had the answer to everything! To my dearest friends at Queen Square, Sudi, Kate, Hil, Perdi, Dan and Idris, your friendships made my UK experience so much more rewarding. I will always cherish your love and care, thank you! I am so grateful for my dear friends Jo, Fran and Lol (fellow PhD buddy) who gave me hugs, smiles and cups of tea when needed most. My study room pals Daniel, Dave, Elias, Sarah, Jacob and Fatima who shared my rants and raves, I thank you all. To my support team Nancy, Jo, Narae, Julie, Danbi, Beks, Jen and Kristy, you girls have helped me maintain my sanity through the past years. Special thanks to Beks, Jen and Kristy for your amazing proof-reading skills and Nancy for being my special shoulder to cry on. I am so grateful for all your prayers and endless encouragement, and keeping me focused on the unseen, your friendships have been invaluable to this journey. My family have put up with so much throughout this journey, I am so deeply grateful. To my mum and brother for believing in me, embracing my breakdowns and your constant prayers and words of comfort has helped me to persevere and continue in running the race. To Jamie, you have been so patient and understanding, I owe alot to you. Thank you for putting up with my tears and struggles, you helped me reach the finish line and I thank you dearly. To my Lord, you showed me that all things are possible through you. Thank you for your grace and guiding me till the very end. I give this and all glory to you. This doctorate was funded by the Australian Government, GlaxoSmithKline Australia and Parkinson’s NSW and a personal thank you to all the brain donors and the Australian Brain Donor Programs. 3 Abstract Idiopathic Parkinson’s disease (PD) and the atypical parkinsonian syndromes progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) have substantial overlap in clinical features, with parkinsonian and cerebellar phenotypes identified. Pathologically, reactive glial changes occur in overlapping pathways in these disorders. Recent findings that glia concentrate proteins associated with genetic forms of PD, suggest a more significant role for these cells in the pathogenesis of these disorders. This study is the first to comparatively assess glial abnormalities in PD, PSP and MSA. Cases were clinically and pathologically characterised to establish correlates to prominent glial changes. The three main types of glia (astrocytes, oligodendroglia and microglia) were characterised by morphological features and protein expression (using immunohistochemical techniques) for correlations with disease indices. Tissue features measured included subregional volumes, nigral cell loss, characteristic disease inclusions, and the densities of glia. Using these techniques, the parkin co-regulated gene protein was found to be a novel constituent protein in protoplasmic astrocytes, facilitating the assessment of glial subtypes. The data show that distinct glial abnormalities associate with each parkinsonian syndrome. The most marked differences were observed in the astrocytic 4 reaction in each disorder. In PD, protoplasmic astrocytes accumulated non- fibrillar -synuclein and degenerated over time, relating to a loss of levodopa responsiveness. In PSP, there was a marked protoplasmic astrogliosis (with these reactive glia strongly expressing parkin) that related to PSP-prominent clinical symptoms. In MSA, there was a marked fibrous astrogliosis and a loss of protoplasmic astrocytes in association with early changes in constituent myelin and oligodendroglial proteins. In contrast, similar microglial activation was observed across all disorders, with phagocytes concentrating in the substantia nigra, while non-phagocytic reactive microglia expressed parkin and associated with inclusion formation in each disorder. Overall, the glial reactions were considered to be either contributing to or ameliorating (neuroprotective) the neurodegenerative processes, and the timing of these reactions assessed with respect to indices of disease progression. The novel findings of this thesis show that glial abnormalities are prominent but distinct, and occur early in these parkinsonian syndromes. Suggestions on how these findings may translate into future therapeutic targets are given. 5 Table of Contents CHAPTER 1: INTRODUCTION............................................................... 22 1.1 Parkinson’s disease and atypical parkinsonian disorders .......... 22 1.1.1 Clinical features and diagnosis ....................................................... 22 1.1.2 Overlapping phenotypes in parkinsonian disorders ........................ 25 1.1.3 Genetics.......................................................................................... 27 1.1.4 Core pathologies differentiating Parkinson’s disease, progressive supranuclear palsy and multiple system atrophy ..................................... 31 1.1.5 Pathological staging and differences between clinical phenotypes. 35 1.1.5.1 Clinicopathological correlates: parkinsonian subtype........ 38 1.1.5.1 Clinicopathological correlates: cerebellar subtype ............ 41 1.1.6 Summary......................................................................................... 43 1.2 Cell specific protein changes in Parkinson’s disease and atypical parkinsonian disorders ......................................................................... 44 1.2.1 Abnormal protein expression in neurons......................................... 44 1.2.2 Abnormal protein expression in astrocytes ..................................... 48 1.2.3 Abnormal protein expression in oligodendroglia ............................. 49 1.2.4 Abnormal protein expression in microglia ....................................... 52 1.2.5 Summary......................................................................................... 53 1.3 Study objectives .............................................................................. 54 1.4 Major hypotheses ............................................................................ 55 CHAPTER 2: COMMON MATERIALS AND METHODS ........................ 56 2.1 Sources of tissue ............................................................................. 56 2.2 Case ascertainment and clinical information................................ 58 2.3 Standard preparation of brain tissue ............................................. 61 2.4 General immunohistochemical methods....................................... 62 2.4.1 Peroxidase immunohistochemistry (counterstained with 6 cresyl violet)............................................................................................. 62 2.4.2 Double-labelling immunofluorescence ............................................ 65 2.4.3 Combined peroxidase and immunofluorescence labelling .............. 66 CHAPTER 3: PATHOLOGICAL STAGING OF PROGRESSIVE SUPRANUCLEAR PALSY...................................................................... 68 3.1 Introduction.....................................................................................
Recommended publications
  • THE CLINICAL ASSESSMENT of the PATIENT with EARLY DEMENTIA S Cooper, J D W Greene V15

    THE CLINICAL ASSESSMENT of the PATIENT with EARLY DEMENTIA S Cooper, J D W Greene V15

    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2005.081133 on 16 November 2005. Downloaded from THE CLINICAL ASSESSMENT OF THE PATIENT WITH EARLY DEMENTIA S Cooper, J D W Greene v15 J Neurol Neurosurg Psychiatry 2005;76(Suppl V):v15–v24. doi: 10.1136/jnnp.2005.081133 ementia is a clinical state characterised by a loss of function in at least two cognitive domains. When making a diagnosis of dementia, features to look for include memory Dimpairment and at least one of the following: aphasia, apraxia, agnosia and/or disturbances in executive functioning. To be significant the impairments should be severe enough to cause problems with social and occupational functioning and the decline must have occurred from a previously higher level. It is important to exclude delirium when considering such a diagnosis. When approaching the patient with a possible dementia, taking a careful history is paramount. Clues to the nature and aetiology of the disorder are often found following careful consultation with the patient and carer. A focused cognitive and physical examination is useful and the presence of specific features may aid in diagnosis. Certain investigations are mandatory and additional tests are recommended if the history and examination indicate particular aetiologies. It is useful when assessing a patient with cognitive impairment in the clinic to consider the following straightforward questions: c Is the patient demented? c If so, does the loss of function conform to a characteristic pattern? c Does the pattern of dementia conform to a particular pattern? c What is the likely disease process responsible for the dementia? An understanding of cognitive function and its anatomical correlates is necessary in order to ascertain which brain areas are affected.
  • Rare Forms of Dementia

    Rare Forms of Dementia

    Rare forms of dementia Final report of a project supported by the Community Rare Diseases Programme 2000-2002 Alzheimer Europe, Route de Thionville 145, L-2311 Luxembourg Rare forms of dementia General Introduction Final report of a project supported by the Community Rare Diseases Programme 2000-2002 This project received financial support from the Commission of the European Communities. The report was produced by a contractor for the Health & Consumer Protection Directorate-General and represents the views of the contractor or author. These views have not been adopted or in any way approved by the Commission and do not necessarily represent the view of the Commission or the Directorate-General for Health and Consumer Protection. The European Commission does not guarantee the accuracy of the data included in this project, nor does it accept responsibility for any use made thereof. Neither the European Commission nor any person acting on its behalf is responsible for any use that might be made of the following information. © European Communities, 2005 Reproduction is authorised, except for commercial purposes, provided the source is acknowledged. Printed by the services of the European Commission, Luxembourg Alzheimer Europe Rare Forms of Dementia Project Table of contents PREFACE 4 INTRODUCTION 8 DEMENTIA – DEFINITION - CONCEPT 12 EXPLANATION OF BRAIN 16 DIAGNOSTIC PROCEDURES 18 CARE AND TREATMENT 27 3 Alzheimer Europe Rare Forms of Dementia Project Preface By Jean GEORGES This report presents the results of the Alzheimer Europe project “Rare forms of dementia” which was financed in the framework of the rare diseases programme of the European Commission. Rare diseases are described by the European Community Action programme as diseases of low prevalence “which is generally recognised as less than 5 per 10,000 in the Community”.
  • Tetrahydroisoquinoline Neurotoxins in Parkinson Disease Michael G

    Tetrahydroisoquinoline Neurotoxins in Parkinson Disease Michael G

    University of Tennessee Health Science Center UTHSC Digital Commons Theses and Dissertations (ETD) College of Graduate Health Sciences 5-2010 Tetrahydroisoquinoline Neurotoxins in Parkinson Disease Michael G. DeCuypere University of Tennessee Health Science Center Follow this and additional works at: https://dc.uthsc.edu/dissertations Part of the Nervous System Diseases Commons, and the Neurosciences Commons Recommended Citation DeCuypere, Michael G. , "Tetrahydroisoquinoline Neurotoxins in Parkinson Disease" (2010). Theses and Dissertations (ETD). Paper 55. http://dx.doi.org/10.21007/etd.cghs.2010.0067. This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized administrator of UTHSC Digital Commons. For more information, please contact [email protected]. Tetrahydroisoquinoline Neurotoxins in Parkinson Disease Document Type Dissertation Degree Name Doctor of Philosophy (PhD) Program Biomedical Sciences Track Neuroscience Research Advisor Mark S. LeDoux, M.D., Ph.D. Committee Joseph C. Callaway, Ph.D. Angela R. Cantrell, Ph.D. Duane D. Miller, Ph.D. Lawrence T. Reiter, Ph.D. DOI 10.21007/etd.cghs.2010.0067 This dissertation is available at UTHSC Digital Commons: https://dc.uthsc.edu/dissertations/55 TETRAHYDROISOQUINOLINE NEUROTOXINS AND PARKINSON DISEASE A Dissertation Presented for The Graduate Studies Council The University of Tennessee Health Science Center In Partial Fulfillment Of the Requirements for the Degree Doctor of Philosophy From The University of Tennessee By Michael G. DeCuypere May 2010 Chapter 2 © 2008 by Wiley-Liss, Inc. Chapter 3 © 2008 by International Society for Neurochemistry.
  • Young Onset Dementia E L Sampson, J D Warren, M N Rossor

    Young Onset Dementia E L Sampson, J D Warren, M N Rossor

    125 Postgrad Med J: first published as 10.1136/pgmj.2003.011171 on 11 March 2004. Downloaded from REVIEW Young onset dementia E L Sampson, J D Warren, M N Rossor ............................................................................................................................... Postgrad Med J 2004;80:125–139. doi: 10.1136/pgmj.2003.011171 Young onset dementia is a challenging clinical problem Mitochondrial diseases have variable inheri- tance, as components of the respiratory chain with potentially devastating medical and social are encoded both by nuclear DNA and mater- consequences. The differential diagnosis is wide, and nally inherited mitochondrial DNA.6 Many of the includes a number of rare sporadic and hereditary dementia-plus syndromes and metabolic disor- ders have ‘‘subcortical’’ cognitive impairment diseases. However, accurate diagnosis is often possible, that may be misinterpreted as a pseudodementia. and all patients should be thoroughly investigated to Changes in personality and mood, apathy and identify treatable processes. This review presents an cognitive slowing are common, whereas memory may be relatively spared. In addition, drugs and approach to the diagnosis, investigation, and management toxic exposures should always be considered in of patients with young onset dementia, with particular younger adults: in approximately 10% of cases, reference to common and treatable causes. YOD is a consequence of chronic alcohol abuse.2 This review will focus on common and ........................................................................... treatable causes of YOD and outline general principles of investigation and management. ementia in younger people (young onset dementia, YOD) is increasingly recognised PRIMARY NEURODEGENERATIONS as an important clinical and social pro- D Alzheimer’s disease blem, with frequently devastating consequences Presenile Alzheimer’s disease may manifest as for both the sufferer and those who care for early as the fourth decade, and it is frequently them.1 Prevalence rates of YOD have been familial.
  • Neurological Manifestations of Wilson's Disease: Pathophysiology and Localization of Each Component

    Neurological Manifestations of Wilson's Disease: Pathophysiology and Localization of Each Component

    Open Access Review Article DOI: 10.7759/cureus.11509 Neurological Manifestations of Wilson's Disease: Pathophysiology and Localization of Each Component Juan Fernando Ortiz 1 , Álvaro Morillo Cox 2 , Willians Tambo 3 , Noha Eskander 4 , Martín Wirth 3 , Margarita Valdez 5 , Maria Niño 6 1. Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Medicine, Universidad San Francisco de Quito, Quito, ECU 3. Neurology, Universidad San Francisco de Quito, Quito, ECU 4. Psychiatry, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 5. Internal Medicine, Universidad Autónoma de Guadalajara, Laredo, USA 6. Emergency Medicine, Universidad del Rosario, Bogotá, COL Corresponding author: Juan Fernando Ortiz, [email protected] Abstract Wilson’s disease (WD) is an autosomal recessive disease that presents mainly with hepatic, neurological, and psychiatric manifestations. Neurological manifestations have been described in the past. Nevertheless, the pathophysiology and the clinical relevance of these manifestations have not been described in great detail in the medical literature. We aim to consolidate the knowledge about the neurological manifestations of WD and present the pathophysiology of each neurological manifestation of the disease. We will give a brief definition, the provenance, and the pathophysiology of the neurological conditions. We collected data from the National Library of Medicine (PubMed) using regular keywords and medical subject headings. Studies were selected applying the following inclusion/exclusion criteria: (1) studies that used exclusively human subjects, (2) papers published in English, and (3) papers from 1990 onward. The exclusion criteria were (1) studies that used animals, (2) papers not published in English, and (3) papers published before 1990. Additional studies were included via reference lists of identified papers and related articles featured in PubMed and Google Scholar.
  • Progressive Supranuclear Palsy Expanding the Clinical and Genetic Spectrum

    Progressive Supranuclear Palsy Expanding the Clinical and Genetic Spectrum

    Progressive Supranuclear Palsy expanding the clinical and genetic spectrum Laura Donker Kaat Financial support for the printing of this thesis was kindly provided by Erasmus University Rotterdam Parkinson Vereniging Boehringer Ingelheim B.V. UCB Pharma B.V. Teva Nederland B.V. Abbott B.V. GRIPP B.V. ISBN: 978-90-5335-481-0 The studies in this thesis were financially supported by the Prinses Beatrix Fonds (grant number 01-0128). Cover: Nikki Vermeulen, Ridderprint BV, Ridderkerk, the Netherlands Lay out: Simone Vinke, Ridderprint BV, Ridderkerk, the Netherlands Printed by: Ridderprint BV, Ridderkerk, the Netherlands Copyright © 2011 by L. Donker Kaat Progressive Supranuclear Palsy expanding the clinical and genetic spectrum Progressieve supranucleaire verlamming: verbreding van het klinisch en genetisch spectrum Proefschrift ter verkrijging van de graad van doctor aan de Erasmus Universiteit Rotterdam op gezag van de rector magnificus Prof. dr. H.G. Schmidt en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op vrijdag 2 december 2011 om 9:30 uur door Laura Donker Kaat geboren te Haarlem Promotiecommissie Promotoren: Prof.dr. P.A.E. Sillevis Smitt Prof.dr. P. Heutink Overige leden: Prof.dr.ir. C.M. van Duijn Dr. V. Bonifati Dr. T. van Laar Table of contents 1. Introduction 7 1.1 General introduction to the thesis 9 1.2 Recent advances in progressive supranuclear palsy: a review 13 2. Clinical heterogeneity 31 2.1 Frontal presentation in progressive supranuclear palsy 33 2.2 Clinimetric characterization of patients with progressive supranu- 47 clear palsy and comparison to patients with Parkinson’s disease 2.3 Survival in progressive supranuclear palsy and frontotemporal 61 dementia 3.